PDCD1 and neoplasm: PD-L1 expression on both tumor cells and immune cells, as well as PD-1 expression on tumor-infiltrating lymphocytes, has been identified as a critical factor that determines the response to immunotherapies targeting the PD-L1/PD-1 axis (26), and have demonstrated to be promising predictive and prognostic biomarkers in NEN (27).